Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 165 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated No phase listed Observational

Establishment of Fibroid Tissue Bank

NCT00710346
Conditions
Leiomyoma, Fibroids
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years to 80 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Symptomatic Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
Interventions
Focused ultrasound (MRgFUS), Uterine artery embolization (UAE)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Durham, North Carolina
Conditions
Uterine Fibroid
Interventions
Body System - Functional
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Stanford, California • Rochester, Minnesota
Conditions
Fibroids, Uterine
Interventions
hysterectomy, Uterine arterial embolization, myomectomy, Medical Therapy, endometrial ablation, magnetic resonance guided focused ultrasound, radiofrequency ablation
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
3,094 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
San Francisco, California • Bethesda, Maryland • Boston, Massachusetts + 6 more
Conditions
Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Metastatic Renal Cell Carcinoma, Skin Leiomyoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Uterine Corpus Leiomyoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mercaptopurine, Questionnaire Administration, Skin Biopsy
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Uterine Fibroids, Anemia
Interventions
Proellex 25 mg, Proellex 50 mg, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 21 more
Conditions
Uterine Fibroids, Endometriosis
Interventions
Relugolix Combination Tablet
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
120
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
Conditions
Leiomyoma, Uterine Hemorrhage
Interventions
Ulipristal acetate (UPA), Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 23 more
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
52
States / cities
Birmingham, Alabama • Arcadia, California • Cerritos, California + 43 more
Conditions
Gynecologic Tumor
Interventions
Magnetic Resonance Fingerprinting (MRF), Q-space Trajectory Imaging (QTI), Magnetic Resonance Imaging Machine (MRI)
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Boston, Massachusetts
Completed No phase listed Observational

Fibroid Growth Study

NCT00340288
Conditions
Uterine Leiomyomas
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Terminated No phase listed Observational

South Miami Hospital Fibroid Registry

NCT02362009
Conditions
Uterine Myomas, Leiomyomas, or Fibromas
Interventions
Not listed
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Conditions
Leiomyoma, Uterine Fibroids, Uterine Neoplasms, Menorrhagia, Leiomyomatosis
Interventions
Uterine Fibroid Embolization (UFE), Contour SE™ Microspheres, Embosphere® Microspheres
Procedure · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Uterine Fibroids, Leiomyoma, Menstrual Pain
Interventions
Elix Daily Harmony
Dietary Supplement
Lead sponsor
Zenchi, Inc.
Industry
Eligibility
20 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Chino, California • Huntington Park, California • San Diego, California + 19 more
Conditions
Leiomyoma, Uterine
Interventions
Green Tea Extract, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland
Completed Early Phase 1 Interventional Accepts healthy volunteers

ICG to Assess Ovarian Perfusion

NCT03927651
Conditions
Fibroid Uterus, Endometriosis, Uterus Myoma, Uterine Fibroid, Uterine Adenomyosis, Endometrial Cyst, Uterine Cyst
Interventions
ICG
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Results available

MyoSure Hysteroscopic Tissue Removal System Registry Study

NCT01369758
Conditions
Uterine Fibroids, Polyps
Interventions
MyoSure Tissue Removal System
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Marlborough, Massachusetts
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
Completed Not applicable Interventional Accepts healthy volunteers

Outcomes on Abdominal Versus Vaginal Morcellation At Time of Hysterectomy

NCT04434066
Conditions
Abnormal Uterine Bleeding, Uterine Bleeding, Fibroid Uterus, Surgery
Interventions
Total Laparoscopic Hysterectomy
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanistic Characterization of Uterine Pain

NCT04145518
Conditions
Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
Interventions
Naproxen Sodium, Placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Evanston, Illinois
Enrolling by invitation Not applicable Interventional

Impact of Educational Videos on Pre-operative Anxiety

NCT07740759
Conditions
Endometriosis, Fibroids, Adenomyosis, Pelvic Pain, Abnormal Uterine Bleeding, Adnexal Mass, Minimally Invasive Gynecologic Surgery, Hysterectomy, Myomectomy, Ovarian Cystectomy, Adnexal Surgery
Interventions
educational video
Other
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Interventions
Relugolix + Estradiol + Norethindrone Acetate
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Marlborough, Massachusetts